Answers are grounded in this paper and cite their sources.
Examines an immunogen series to enhance VRC01-class B cell responses, suggesting a novel approach for HIV-1 vaccination.
A five-dose sequential immunogen series designed to guide germline VRC01-class B cells toward the HIV-1 gp120 CD4-binding site. Designed and validated using AlphaFold, ProteinMPNN, and PDB structures 3NGB/5IES/5IDL. The series achieves pTM scores of 0.83-0.91 across all doses, with 11/11 critical CD4-binding site contact residues preserved throughout. AlphaFold Multimer ipTM was consistent across all five immunogens (0.56-0.57), matching the eOD-GT8 baseline. An empirical safety limit of 28 residue substitutions per step was discovered.
No takes yet. Share an insight, caveat, or question.
AHMED SAEED AL GHAMDI (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: